FindTrial
Sign In

GI-102

DRUG2 trials

Sponsors

GI Innovation, Inc.

Conditions

Advanced Solid TumorColorectal Cancer (CRC)Cutaneous MelanomaHER2 Negative Breast CancerHepatocellular Carcinoma (HCC)Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Solid TumorPlatinum-resistant Ovarian Cancer (PROC)

Phase 1

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RecruitingNCT05824975
GI Innovation, Inc.Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS) +6
Start: 2023-05-30End: 2027-04-24Target: 358Updated: 2024-11-25
GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
RecruitingNCT07871435
GI Innovation, Inc.Metastatic Castration-resistant Prostate Cancer (mCRPC)
Start: 2026-10-12End: 2029-09-30Target: 107Updated: 2026-10-19

Related Papers

Trial in progress: A Phase 2a Study of GI-102 (CD80/IL2v3) as a consolidation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma following anti-CD19 chimeric antigen receptor T-cell therapy (CARNATION trial)
Blood2025-11-03
A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation.
Journal of Clinical Oncology2024-06-011 citations
729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
Regular and Young Investigator Award Abstracts2023-10-31